Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Danaher Corporation (DHR) vs iShares MBS ETF (MBB) Price & Performance

Danaher CorporationTrade
iShares MBS ETFTrade

Price performance (Past 24H)

Key statistics

Danaher Corporation vs iShares MBS ETF — how do they compare? Danaher Corporation trades at $218.41 (market cap $152.87B), while iShares MBS ETF trades at $89.7 (market cap $35.41B). The key difference: Danaher Corporation is far larger — about 4.3× iShares MBS ETF's market cap, and Danaher Corporation pays a 0.74% dividend while iShares MBS ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Danaher Corporation for 69 Days and iShares MBS ETF for 96 Days on average.

DHRMBB
Market Cap
$152.87B$35.41B
Volume
5,228,6985,388,525
Sector
HealthFixed Income
52-Week High
$242.05$96.91
52-Week Low
$161.91$89.09
Typical Hold Time
69 Days96 Days
Enterprise Value
$175.08B—
Dividend Yield
0.74%—

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Danaher Corporation

Danaher (DHR) trades at $218.49, up 1.36% on the day, with a bullish technical signal and consistent earnings beats in recent quarters. The stock shows strong profitability with a 58.51% gross margin and 15.95% net income margin, though revenue growth has been modest. Analyst consensus is strongly bullish with a $230.31 price target, supported by institutional buying activity and a recent dividend announcement.

The outlook for DHR is positive, driven by earnings momentum and institutional confidence, but risks include elevated valuation multiples and competitive pressures in the healthcare sector. Investors should weigh the strong analyst support against potential margin compression and macroeconomic headwinds affecting capital spending.

iShares MBS ETF

MBB (iShares MBS ETF) trades at $89.22, down 0.16% amid bearish technical signals with 18 sell indicators versus 2 buy signals. The ETF faces pressure from rising intermediate-term rates and inflation concerns, with short interest surging 98.3% in September 2026 to 6.57 million shares. Recent institutional activity shows mixed sentiment with some firms increasing positions while technical indicators point to continued downward momentum.

The outlook remains challenging with convexity risk and borrower prepayment optionality limiting upside potential. Investment opportunity exists for income-focused investors through consistent dividend payments, but risks include duration exposure during potential rate hikes and persistent inflation pressures affecting mortgage-backed securities performance.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

DHR
18% Buy82% Sell
Avg holding period · 69 Days
MBB
100% Buy0% Sell
Avg holding period · 96 Days

Top news

Latest headlines on both assets

About Danaher Corporation

In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.

Read more on DHR →

About iShares MBS ETF

The fund will invest at least 80% of its assets in the component securities of the underlying index and TBAs that have economic characteristics that are substantially identical to the economic characteristics of the component securities of the index, and the fund will invest at least 90% of its assets in fixed income securities included in the underlying index that advisor believes will help the fund track the index.

Read more on MBB →